4093-41-8

Usage

Uses

Used in Pharmaceutical Industry:
METHYL 4-(ACETYLAMINO)-2-METHOXY-5-NITR& is used as an intermediate in the synthesis of various drugs. It plays a crucial role in the development of pharmaceutical compounds, contributing to the creation of new medications for treating various diseases and conditions.
Used in Agrochemical Industry:
In the agrochemical sector, METHYL 4-(ACETYLAMINO)-2-METHOXY-5-NITR& is utilized as an intermediate in the production of pesticides. Its involvement in the synthesis of agrochemicals helps in developing effective solutions for pest control and crop protection, ensuring increased agricultural productivity.
Used as a Research Chemical:
METHYL 4-(ACETYLAMINO)-2-METHOXY-5-NITR& is also used as a research chemical in both the pharmaceutical and agricultural industries. It aids scientists and researchers in studying the properties, reactions, and potential applications of METHYL 4-(ACETYLAMINO)-2-METHOXY-5-NITR&, furthering the understanding of its role in chemical synthesis and development.

InChI:InChI=1/C11H12N2O6/c1-6(14)12-8-5-10(18-2)7(11(15)19-3)4-9(8)13(16)17/h4-5H,1-3H3,(H,12,14)

Upstream product

• 27492-84-8 Methyl 4-amino-2-methoxybenzoate 
• 4093-29-2 methyl 4-(acetylamino)-o-anisate 

Downstream Products

• 156601-89-7 methyl 4-(N-acetyl-N-methylamino)-2-methoxy-5-nitrobenzoate 
• 59338-84-0 methyl 4-amino-2-methoxy-5-nitrobenzoate 
• 59338-85-1 methyl-4,5-diamino-2-methoxybenzoate 
• 1219014-67-1 ethyl 4,5-diamino-2-methoxybenzoate 
• 1219014-66-0 ethyl 4-amino-2-methoxy-5-nitrobenzoate 
• 59338-91-9 2-methoxy 4,5-diamino benzoic acid 
• 1027073-25-1 N-[4-(1-Hydroxy-4-methyl-5-pyridin-3-yl-1H-imidazol-2-yl)-5-methoxy-2-nitro-phenyl]-N-methyl-acetamide 
• 156601-92-2 N-[5-Methoxy-4-(5-methyl-4-pyridin-3-yl-1H-imidazol-2-yl)-2-nitro-phenyl]-N-methyl-acetamide 
• 126436-38-2 2-(4-Amino-3-chloro-2-methoxy-5-nitro-phenyl)-4-methyl-5-pyridin-3-yl-imidazol-1-ol 
• 126436-41-7 2-Chloro-3-methoxy-4-(5-methyl-4-pyridin-3-yl-1H-imidazol-2-yl)-6-nitro-phenylamine 
• 1026638-96-9 N-[2-Amino-5-methoxy-4-(5-methyl-4-pyridin-3-yl-1H-imidazol-2-yl)-phenyl]-N-methyl-acetamide 
• 1025879-92-8 N-[2-Amino-5-methoxy-4-(5-methyl-4-pyridin-3-yl-1H-imidazol-2-yl)-phenyl]-acetamide 
• 126436-42-8 2-(4-amino-2-methoxy-5-nitrophenyl)-5-methyl-4-(3-pyridyl)imidazole 
• 156601-86-4 3-Chloro-4-methoxy-5-(5-methyl-4-pyridin-3-yl-1H-imidazol-2-yl)-benzene-1,2-diamine 

Relevant academic research and scientific papers

ACTIVATORS OF THE RETINOIC ACID INDUCIBLE GENE "RIG-I' PATHWAY AND METHODS OF USE THEREOF

The present invention is directed to compounds of Formula (I), which are activators of the RIG-I pathway.

ACTIVATORS OF THE RETINOIC ACID INDUCIBLE GENE "RIG-I" PATHWAY AND METHODS OF USE THEREOF

The present invention is directed to compounds of Formula (I), which are activators of the RIG-I pathway.

As neuroprotective agents of pharmaceutical compounds

The invention discloses a medicinal compound as a neuroprotective agent. The medicinal compound is a neuronal nitric oxide synthase-postsynaptic density protein 95 (nNOS-PSD95) decoupling agent. The medicinal compound is a benzene ring derivative shown in the general formula (I) or its pharmaceutically acceptable salt. The invention further discloses a preparation method of the medicinal compound and a use of the medicinal compound in prevention and treatment on neuronal damage influence-caused diseases.

RADIOPROTECTOR COMPOUNDS AND METHODS

The invention relates to novel compounds, processes for their preparation and their use in protecting biological materials from radiation damage (radioprotection). Preferred compounds of the invention are those of Formula (II), as follows: wherein W represents -N(R1R2) where R1 and R2 are not both hydrogen and where they may together form a 5, 6 or 7 membered ring structure, -NHN(R1R2), NHR3N(R1R2), -NHR3OR2, -N(R3)R3OR2, -N(R1)R3OR3OR3, OR3NR1R2, -OR3 or W represents piperidyl, piperazinyl, morpholinyl, thiomorpholinyl or diazepanyl each of which may be optionally substituted by C1 to C4 alkyl, C2 to C4 alkenyl, -N(CO)N(R1R2), -N(CO)OR1, -N(CO)OR3OH, -(CO)NR1R2, -R3(CO)NR1R2, -R3OR1, -OR1, -N(R1R2) OR -NH-; R1 and R2 are the or different and are selected from hydrogen, C1 to C4 alkyl or C2 to C4 alkenyl; group or chain; Z is the same or different and represents N or CH; Z' is the same or different and represents N or C; X represents CH, N or NH, where .. is a double bond when X is CH or N and a single bond when X is NH; X' represents N or NH, wherein when X is CH or N X' is NH and wherein X and X' are different and further where ～～～is a double bond when X' is N and a single bond when X' is NH; Q represents H, alkoxyl, -NR1R2, F or Cl; Q1 is absent when Z' is N and when Z' is C it represents H, alkoxyl, -NR1R2, F or Cl; A represents a five to ten membered single or multiple ring structure with heterocyclic N or O located at the ortho position, said ring including optional double bonds, substitutions and/or other heteroatoms and pharmaceutically acceptable derivatives thereof.

Investigation of novel 7,8-disubstituted-5,10-dihydro-dibenzo[b,e][1,4]diazepin-11-ones as potent Chk1 inhibitors

The synthesis and structure-activity relationships (SAR) of Chk1 inhibitors based on a 5,10-dihydro-dibenzo[b,e][1,4]diazepin-11-one core are described. Specifically, an exploration of the 7 and 8 positions on this previously disclosed core afforded compounds with improved enzymatic and cellular potency.

A novel series of 6-methoxy-1H-benzotriazole-5-carboxamide derivatives with dual antiemetic and gastroprokinetic activities

A novel series of 6-methoxy-1H-benzotriazole-5-carboxamide derivatives with a medium perhydroazacycle ring in the amine moiety were prepared, and their antiemetic and gastroprokinetic activities were evaluated. Among them, N-(1-ethylhexahydroazepin-3-yl)-, N-(1-ethyloctahydroazocin-3-yl)- and N-(1- ethyloctahydroazonin-3-yl)-6-methoxy-1H-benzotriazole-5-carboxamides (24, 36, 37) showed a potent antiemetic activity (inhibition of apomorphine-induced emesis in dogs) along with gastroprokinetic activity (gastric emptying in rats).